Labcorp Gains on Covance Synergy, Diagnostics Strength: Labcorp has been gaining momentum from its Covance drug development business and solid diagnostic services. It's exploring further opportunities in strategic synergies.
Shareholder Meetings: Labcorp holds periodic Webcasts and live streams for its shareholders to keep them updated on financial results and company strategy.
CEO Compensation: However, CEO is unlikely to see a pay rise this year.
Acquisition: The company recently acquired select assets of Invitae, expanding their range of diagnostic testing capabilities. This acquisition was approved by US Bankruptcy Court.
First Quarter Earnings 2024: While Labcorp's revenues surpassed expectations, EPS missed forecasts. Nevertheless, the company has raised its EPS 2024 view.
Dividend: Labcorp has regular dividend payouts, with the recent dividend declared at $0.72.
Investor Sentiment: Although there's some criticism regarding Labcorp's valuation, the company's stock performance has been generally resilient.
Innovations: Recent FDA approval of a colorectal cancer test developed by Labcorp's partner, Geneoscopy, and launch of an at-home test kit signal an innovative approach in the clinical diagnostics segment.
Laboratory Corporation of America Holdings LH News Analytics from Mon, 03 Jul 2023 07:00:00 GMT to Sun, 12 May 2024 21:06:20 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
